Effects of psychedelics on subjective and objective sleep outcomes: A systematic review and exploratory meta-analysis
Xin Yang, Shuping Fang, Kejia Hu, Wenqi Lyu, Yilin Liu, Yuan Shi, Lu Tan, Rong Ren, Ye Zhang, Weihong Kuang, Xiangdong Tang
Therapeutic Advances in Psychopharmacology October 1, 2026 DOI: 10.1177/20451253261502573 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review and exploratory meta-analysis Peer reviewed |
|---|---|
| Sample size | 1,975 |
| Population | Adults receiving classic psychedelics, MDMA, or ketamine and reporting sleep outcomes or sleep-related adverse events |
| Interventions | Classic psychedelics MDMA ketamine |
| Key findings | Controlled MDMA studies suggested improved subjective sleep quality in the subacute phase versus controls (Hedges' g = -0.78), and uncontrolled MDMA follow-up showed within-group improvement (g = -0.63). Ketamine did not show a statistically significant within-group improvement in subjective sleep quality (g = -0.45). Evidence for classic psychedelics was insufficient for meta-analysis, and sleep-related adverse events were generally mild and transient. |
Abstract
Background: Psychedelics, including classic psychedelics, 3,4-methylenedioxymethamphetamine (MDMA), and ketamine, are increasingly investigated for psychiatric disorders, but their effects on sleep remain unclear.
Objectives: To systematically evaluate the effects of these interventions on subjective and objective sleep outcomes and summarize sleep-related adverse events.
Design: A systematic review and exploratory meta-analysis was conducted. Subjective and objective sleep outcomes were synthesized using random-effects models with standardized mean differences (Hedges’ g) and 95% confidence intervals (CI). Meta-analyses were stratified by study design and post-administration assessment phase. Data Sources and
Methods: Embase, PubMed, Web of Science, and the Cochrane Library were searched from inception to March 15, 2026. Eligible studies included adults receiving classic psychedelics, MDMA, or ketamine and reporting subjective or objective sleep outcomes or sleep-related adverse events. Objective sleep measures assessed by polysomnography or actigraphy were extracted when available.
Results: Thirty-two reports representing 30 independent studies and 1,975 participants were included. Evidence for classic psychedelics was limited, with insufficient data for meta-analysis. Controlled MDMA studies during the subacute phase suggested improved subjective sleep quality compared with controls (Hedges’ g = -0.78; 95% CI -1.40 to -0.17; I 2 = 14.4%; very low certainty). Uncontrolled MDMA studies during follow-up also showed within-group improvement (Hedges’ g = -0.63; 95% CI -1.13 to -0.14; I 2 = 0%). Ketamine studies did not demonstrate a statistically significant within-group improvement in subjective sleep quality during the subacute phase (Hedges’ g = -0.45; 95% CI -1.04 to 0.14; I 2 = 88.8%). Sleep-related adverse events were generally mild and transient, including insomnia, hypersomnia, and unpleasant dreams.
Conclusion: Psychedelics may have compound-specific and time-dependent effects on sleep. However, the evidence remains preliminary because of small samples, heterogeneous designs, and limited objective and long-term data.
Citations in the library
Cites 42
- Single-Dose Psilocybin Treatment for Major Depressive Disorder JAMA August 31, 2023
- 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. The Lancet Psychiatry May 1, 2018
- Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology December 25, 2017
- Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine Journal of Neuroscience November 30, 2020
- Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder The International Journal of Neuropsychopharmacology June 7, 2012
and 37 more in the library